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(57) ABSTRACT 
A device and method in accordance with the invention for 
determining the oxygen partial pressure (PO,) of a tissue by 
irradiating the tissue with optical radiation such that the light 
is emitted from the tissue, and by collecting the reflected or 
transmitted light from the tissue to form an optical spectrum. 
A spectral processor determines the PO, level in tissue by 
processing this spectrum with a previously-constructed 
spectral calibration model. The tissue may, for example, be 
disposed underneath a covering tissue, such as skin, of a 
patient, and the tissue illuminated and light collected 
through the skin. Alternatively, direct tissue illumination and 
collection may be effected with a hand-held or endoscopic 
probe. Apreferred system also determines pH from the same 
spectrum, and the processor may determine critical condi- 
tions and issue warnings based on parameter values. 
24 Claims, 3 Drawing Sheets 
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TISSUE OXYGEN MEASUREMENT SYSTEM 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
Tissue oxygenation is traditionally determined through 
the measurement of the partial pressure of oxygen (PO,) 
present in the cells or the interstitial fluid. Typically, tissue 
PO, is measured by inserting an invasive PO, sensor (such 
s as an electrode-based sensor or a dye-coated fiber optic 
sensor) into the tissue that is to be monitored. 
could be made spectroscopically, such that the measurement 
process is non-invasive and does not physically penetrate or 
10 stress the tissue. A number of researchers have investigated 
spectroscopic methods to determine tissue oxygenation, In 
This invention was made with government support under doing so, they have typically relied upon quantifying some 
National Space Biomedical Research Institute contract no. related parameter, F~~ researchers have 
NCC9-58-226 under NASA Agreement NCC9- considered the spectroscopic measurement of arterial or 
58; the government of the United States of America may 15 venous blood oxygen to constitute a suitable measure of 
have certain rights in the invention. tissue oxygenation. Arterial blood levels do not, however, 
This application is based on U.S. provisional application 
No. 601329,406, entitled “Tissue Oxygen Measurement 
System,” filed on Oct, 15,2001, of which priority is claimed, Ideally, it would be advantageous if this measurement 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
FIELD OF THE INVENTION 
respond rapidly to regional changes in reduced oxygen, so 
this indicator may fail to reflect urevailing tissue oxygen- 
Tissue levels of oxygen are an important indicator of the 
metabolic status of cells. If tissue oxygen falls below cellular 
demands, then cells perish. Organs, particularly those with 
high metabolic rates, are especially susceptible to incurring 
irreversible damage when oxygen is inadequate. It has 
previously been shown that tissue pH is a useful indicator of 
anaerobic metabolism, and as such can indicate cells at risk. 
However, tissue oxygen levels change prior to a drop in pH, 
so that detection of a low oxygen level could provide an 
earlier indication of a potential problem. Measurement of 
tissue oxygenation could also provide a useful early measure 
to assess the degree of success in restoring oxygen to 
oxygen-deficient tissue. 
Cellular processes are complex, and beyond the question 
of whether oxygen is transported to the cells in sufficient 
quantity, one may ask whether the cells are able to use the 
available oxygen. The combination of a tissue pH measure- 
ment and a tissue oxygen measurement would be useful in 
determining whether a given tissue bed can actually utilize 
for example, in U.S. Pat. No. 5,879,294 andpossibly other 
patents, and also in promotional material or research pub- 
lications of that group. Another company, Somonetics, sells 
30 a NIR device which measures a combination of venous and 
arterial oxygen saturation in the brain. A large number of 
issued patents are also directed to various optical methods of 
measuring blood and tissue levels of oxygenated hemoglo- 
bin or oxygen saturation. These include, for example, U.S. 
35 Pat. Nos. 5,515,864, 5,593,899, 5,931,799, 6,015,969, 
6,123,597, and 6,216,021. Dr. Britton Chance at the Uni- 
versity of Pennsylvania has also patented a number of 
inventions in this area. 
In general, known devices and methods for evaluating the 
40 level of oxygen have tended to rely on secondary or related 
measurements, or upon relatively invasive sensors or slower 
assays. 
It would therefore be desirable to have a system that 
determines tissue PO, directly and non-invasively in a local 
tissue region. 45 . 
SUMMARY OF THE INVENTION oxygen which is delivered. In a recent paper, applicant has shown that the simultaneous measurement of tissue uH and 
oxygenation can be used to indicate the onset of dysoxia 
(defined as the mismatch between oxygen demand and 
supply). Soller et al., “Application of fiberoptic sensors for 
the study of hepatic dysoxia in swine hemorrhagic shock,” 
Crit. Care Med, 29:1438-1444 (2001). The detection of the 
onset of dysoxia in this manner may therefore permit earlier 
or more effective preventive interventions in humans. 
However, the technology for measuring these parameters is 
at present limited. 
Solving this need would be a major contribution to 
clinical practice. Clinically, oxygen levels can change as a 
result of many causes: bleeding, trauma, poor cardiac 
performance, low blood pressure and impaired circulation, 
A device in accordance with one aspect of the invention 
50 determines the oxygen partial pressure (PO,) of a tissue, 
which may, for example, be disposed underneath a covering 
tissue, such as skin, of a patient, or which may be directly 
contacted or imaged by the device. The device includes a 
light source for irradiating the tissue with optical radiation 
55 such that the light is reflected from the tissue, and also 
includes a probe for collecting the reflected light to form a 
reflection spectrum. The device further includes a spectral 
processor that determines the PO, level in tissue by pro- 
cessing this spectrum and a mathematical model relating 
A method of the invention includes the step of first 
60 optical properties to PO, of the tissue. 
among others. Diabetic patients often have compromised illuminating the tissue with optical radiation to irradiate the 
tissue perfusion, particularly in their legs and feet. This may underlying tissue, and collecting a reflection spectrum from 
result in ulcers and ultimately require amputation. For the illuminated tissue. The method also includes the step of 
management of such a chronic condition, it would be 65 determining tissue PO, by processing the collected spectrum 
especially desirable to possess a technique or sensor for with a mathematical model relating optical properties to PO, 
dependably monitoring tissue oxygenation, of the tissue. 
US 6,766,188 B2 
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The invention also includes a spectral calibration model during which the tissue PO, and other conditions vary over 
for tissue PO,. The model is constructed from a previously a wide range. The calibration model is then constructed from 
compiled calibration data set comprised of direct PO, mea- the calibration set, and is subsequently applied to the spec- 
surements and a set of spectral samples collected in coor- trum collected from the local region in the tissue of interest. 
dination with the measurements. 5 In this manner, tissue PO,, which itself has no “spectrum”, 
By “tissue”, as used herein, is meant any tissue or organ is accurately and quickly detected by processing light non- 
present, e.g., in a patient. This definition encompasses any invasively collected at the surface of the local region of 
collection of cells, e.g., epithelial cells, muscle cells, skin tissue. 
cells, or any specific organ, e.g., the heart, kidney, or liver, It is known that a related parameter (e.g., venous oxygen 
in the patient. The optical radiation preferably is visible and saturation) may be spectrally measured, for example, by the 
near infrared radiation or includes a substantial range of near methods reported by Cingo et  al. in Proc SPIE, 
infrared radiation. The radiation may be between about 400 3911:230-236, (2000) or by Soller et al. in Shock, 
and about 2500 nm, and preferably, the radiation is between 15:106-111, (2001), or other known assay, and that venous 
450 and 1100 nm. oxygen saturation is linearly related to tissue PO, in the 
The mathematical model of the invention is constructed 15 range between about 15% and about 80% saturation. Since 
prior to processing a collected spectrum by first compiling a a number of spectrally significant contributors to oxygenated 
calibration data set. The calibration data set is formed by and deoxygenated hemoglobin, as measured by venous 
collecting multiple optical spectra from a representative oxygen saturation, are present in the tissue and contribute to 
tissue sample of a subject, and also measuring the tissue PO, the tissue spectrum, the present invention has discovered 
value simultaneously (e.g., by conventional means). Prefer- 2o that by applying a multivariate fitting algorithm to local PO, 
ably such data sets are collected from multiple subjects and measurements and local tissue spectra, it might be possible 
Over a wide range of PO, values. The optical spectra and to develop a “virtual model” of PO,. During the initial 
known PO, values are then processed with a mathematical calibration model development, the reference PO, 
multivariate calibration algorithm, such as a partial least- measurements, may, for example, be taken by an invasive 
squares (PLS) fitting algorithm described below, to deter- 25 tissue PO, sensor placed directly in the target tissue or 
mine a model, e.g. a formula or calibration equation, relating organ. Similarly, the spectrum may be collected from the 
PO, to the spectral values collected from the sample. In same tissue site. The model so developed will then accu- 
constructing the model, other parameters, such as pH, tem- rately represent PO, itself, rather than a few closely related 
perature and the like may also be measured and fitted to the but potentially divergent factors. 
model, and these subject pH, temperature or other param- 30 The set of spectral and direct measurements for defining 
eters may also be measured at run time for enhanced the calibration model are preferably collected as the PO, 
accuracy. In another embodiment, one or more parameters level (and other parameters) are varied over an extended 
such as pH, temperature or the like may be varied during range. In a proof-of principle example to construct a Cali- 
acquisition of the calibration data set, serving to enhance the bration equation or model for spectral measurement of tissue 
variety of conditions covered by the model, and hence, its 35 PO,, tissue reflectance spectra and raw data measurements 
accuracy, without becoming explicit variables in the cali- are taken every thirty seconds from the muscle of a patient’s 
bration formula so produced. palm as the patient undergoes a cardiopulmonary bypass 
Once determined, the model is stored, e.g., in the memory (CPB) procedure. The CPB procedure introduces great 
of a computer, and then used to transform the optical changes in pH, mean arterial blood pressure and PO, over 
spectrum obtained from a patient into a PO, value for the 40 the course of more than an hour for each subject, before the 
underlying sample tissue. Most preferably, the model used in patient’s heart is stopped, the subject is placed on the 
the analysis step is determined once and is applicable to a heart-lung machine and cooled, and the subject is subse- 
wide variety of patients. In this case, the model is preferably quently re-warmed and revived. Data is preferably collected 
robust enough to account for features such as skin color, fat from diabetic and non-diabetic patients, to introduce further 
content, weight, etc., which vary from one patient to the 45 range or additional variation in the tissue response data. 
next. Alternatively, a range of models can be generated. In The resulting data set with multiple embedded parameter 
this case, during a procedure, the model suitable for a variations is then processed to develop a calibration model 
particular patient is selected and is then used to determine for determining tissue PO, from the collected reflectance 
the tissue PO, from spectra acquired from that patient. In yet spectra returned from the underlying muscle. This model, 
a different embodiment, a special calibration formula may 50 that is to be later applied to independently-collected spectra 
developed to correct for a specific spectral contribution (e.g., from arbitrary subjects, is determined prior to taking a run 
the contribution of skin scattering and coloration in spectra time reflectance or transmittance spectrum by collecting 
from individuals of diverse ethnicity), and this special multiple optical spectra, each occurring at known PO, 
calibration formula may be used to pre-process or normalize values, from a representative sample. The optical spectra 
the spectrum obtained from a given patient prior to applying 5s and known PO, values are then processed with a mathemati- 
the PO, calibration equation. Suitable procedures for effect- cal multivariate calibration algorithm, such as a partial 
ing such spectral correction are described in commonly- least-squares (PLS) fitting algorithm, to derive the calibra- 
owned U.S. patent application Ser. no. 101086,917, filed on tion model. The model may feature a linear or non-linear 
Feb. 28, 2002, and which is hereby incorporated by refer- mathematical equation relating actual level of PO, to a 
ence in its entirety. 60 reflection or absorption spectrum taken from the sample. 
The calibration model is a synthetic construct, and is Once constructed or verified, the model is applied to 
previously and independently constructed by a procedure of independently-gathered spectra to quantify tissue PO, 
first collecting a calibration set comprising a plurality of directly, non-invasively and in real time. 
reflected or transmitted light samples from tissue, and also Thus, the invention provides an optical method for deter- 
a plurality of direct PO, reference measurements from the 65 mining the oxygen partial pressure in a tissue. The target 
same tissue, where the light samples and reference measure- tissue may, for example, be disposed underneath a covering 
ments are taken in an extended data collection protocol tissue (for example, muscle tissue illuminated through the 
US 6,766,188 B2 
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overlying skin), or may be directly accessed by the optical 
probe (for example, cardiac tissue having an exposed surface 
and accessed during open chest or minimally-invasive sur- 
gery by a fiber optic surface contact probe, or by a focused 
illuminatoricollector probe). 
BRIEF DESCRIPTION OF THE DRAWINGS 
These and other features and advantages of the invention 
will be understood from the description herein and claims 
appended hereto, taken together with illustrative figures, 
wherein: 
FIG. 1 is a flow chart showing the steps used for PO, 
measurement according to the method of the invention; 
FIG. 2 is a comparison chart showing PO, determined by 
direct sensor measurement and determined by the method of 
the present invention; 
FIG. 3 is a chart showing tissue PO, during four different 
phases of the study as determined by the method of the 
present invention; and 
FIG. 4 shows a measurement system in accordance with 
the present invention. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention provides a method that determines 
the partial pressure of oxygen (PO,) in a region of a 
subject’s tissue by collecting a sample of reflected or trans- 
mitted light from the tissue and then processing the sample 
with a series of computational steps. The sample is a spectral 
sample, with light spanning a number of frequencies (or, 
equivalently, wavelengths), and is detected such that the 
spectrum may be represented numerically, e.g., as a row 
vector with entries corresponding to the intensity value for 
each of a number of sub-intervals of the spectral band. The 
spectrum is processed by applying a mathematical model 
that relates distribution of values in the spectrum to the 
actual level of tissue PO,. The general technique of deriving 
a calibration equation or model for assay of a material 
having a defined reflectance spectrum but presented in a 
confounding background such as tissue is described in 
numerous papers, including those previously cited, in U.S. 
Pat. No. 5,813,403 by Soller, and elsewhere. A specific 
derivation will be described further below for tissue oxygen 
partial pressure. Of particular note is the discovery that by 
constructing a “virtual” model for the spectrum of the partial 
pressure of free oxygen present in tissue, one may directly 
measure PO, by simply applying the model to a non- 
invasively collected light sample (technically, tissue PO, is 
a condition that affects many contributing factors, rather 
than being a substance having a distinct spectrum). 
The virtual PO, model, or calibration equation, is con- 
structed prior to collecting and processing the optical spec- 
trum of a local region of tissue in which PO, is to be 
measured. The model can be constructed, as described in 
greater detail below, by taking a series of spectra from tissue 
samples having known and widely ranging PO, values, and 
then processing the spectra and the PO, values with a partial 
least squares (PLS) fitting algorithm. Once so constructed, 
this virtual PO, model is applied to determine PO, from a 
collected tissue spectrum, e.g., comparing the spectrum to 
the model. 
An overall procedure for effecting a spectral measurement 
in accordance with the invention is shown in FIG. 1, a flow 
chart illustrating process steps effective to determine the 
tissue PO, of a sample. A model of tissue PO, is first 
S 
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generated with a series of steps indicated generally by the 
bracket 11 in FIG. 1, and the model is stored, e.g., in a 
computer memory. The model is then accessed later in time 
and used in combination with a second series of steps, 
indicated generally by the bracket 13, to determine the 
oxygen partial pressure in tissue at the sampled region. 
To construct the model, optical data (reflectance spectra) 
are collected from the sample and PO, is concurrently 
measured with a known reference sensor (step 10). During 
the collection process, the level of PO, varies over a great 
range, so that the collected data set represents spectra and 
PO, readings over that range. In a prototype implementation 
discussed further in the EXAMPLE below, the reference 
sensor can be a 0.5 mm reference sensor distributed by 
Diametrics Medical, Inc., that measures three parameters: 
pH, PO,, and temperature. In the study discussed in detail 
below, reference PO, and pH sensors were placed directly in 
a muscle, the abductor digiti minimi (V). A separate, near 
infrared spectroscopic (NIRS) fiber optic probe (such as the 
optical fiber spectral probe of the aforesaid ’403 patent) was 
placed over the hypothenar eminence (palm muscle) to 
collect light returned from the same palm muscle. Data were 
collected every 30 seconds during the course of a surgery 
and for 6 hours following CPB to acquire a set of spectra, 
each with a corresponding PO, measurement, as the PO, 
varied over an extended range of values. In general, one may 
arrange for the PO, to be varied using any known technique, 
such as by constricting a vessel or otherwise adjusting the 
blood flow to the sampled region of the patient’s tissue. In 
the prototype construction, such variation was arranged by 
collecting the data during a major surgery, a cardiopulmo- 
nary bypass operation, in which the various surgical steps- 
placing the subject on a heart-lung machine, stopping 
patient’s heart, and subsequently re-warming and reviving 
the patient-induced changes in PO, over a range from low 
or even zero to normal values, over the course of several 
hours. Because the PO, of a muscle (or other) sample may 
exhibit a spatial dependence, the reflectance spectrum was 
collected from an area of the tissue in close proximity to the 
reference sensors. 
In the prototype procedure for collecting a spectral/ 
measurement calibration data set from which the model was 
to be constructed, 18 elective cardiac surgical subjects were 
each sampled during a respective CPB surgery. 
Continuing with a discussion of FIG. 1, the data collected 
at stage 10 may be preprocessed or may be collected in 
various ways in a stage 17 to enhance its information 
content. The data set is then processed at stage 12 with a 
numerical algorithm to construct a calibration equation or 
model. Preprocessing may include filtering using known 
smoothing algorithms to improve their signal-to-noise ratio, 
for instance, when data contains large amounts of noise. 
Preprocessing may also include removing spectral factors 
related to human subject variability, such as skin color as 
discussed in U.S. patent application Ser. No. 101086,917 
previously cited, and which is hereby incorporated by ref- 
erence. A technique such as mean-centering may also be 
applied in a pre-processing stage prior to processing with the 
numerical algorithm. In this case, x-y arrays corresponding 
to different PO, values are averaged together to generate an 
average x-y array; the average x-y array is then subtracted 
from each individual x-y array taken at different PO, values 
using Equation 1 below: 
9ck=YtkEYc,ave 
where the “hat” over yLk indicates the data point is normal- 
ized by the mean-centering operation. Other pre-processing 
US 6,766,188 B2 
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routines may be useful, such as taking a first or second tion spectra in the form of the x-y arrays of data points and 
derivative of the spectra prior to processing, or making the PO, of the sample. Based in part on this regressive 
multiplicative scatter corrections to the spectra (see, e.g., H. analysis, the PLS algorithm generates a mathematical model 
Martens and T. Naes, “Multivariable Calibration”, J. Wiley (step 16) with regression coefficients that are optimized to 
& Sons (1989)). s best fit the input data. The algorithm may also generate other 
Thus, for example, multiple samples may be taken and statistical information, as discussed in the aforesaid ’403 
averaged at each point, and/or a reflector phantom may be patent, indicating the quality and accuracy of the model. It 
positioned on the tissue to provide a reference spectrum used should be noted that when the given tissue conditions 
to normalize the collected tissue reflectance spectra. Also, suggest that a non-linear relationship exists, then a different 
both actual PO, measurements and optical measurements i o  multivariate fitting procedure may be employed to enhance 
can be recorded from multiple localized areas, with values the accuracy of the model. 
averaged together to increase the robustness or accuracy of In a qualitative sense, the PLS algorithm determines 
the data. PO,-induced changes in the reflection spectra and correlates 
The actual (conventionally-measured) PO, reading of the these to the PO, value. For example, chemical species such 
sample, and parameters such as the temperature and pH, if is as myoglobin and hemoglobin contained in tissue samples 
measured, are each recorded as a single numerical value, have absorption properties which are PO,-dependent; as the 
while the reflection spectrum is in the form of an x-y array PO, changes, the absorption spectra of the tissue also 
of points. The x values of the array represent particular changes. The PLS algorithm interprets changes in each x-y 
optical wavelengths or frequencies, while they values rep- array induced by PO,, and generates a mathematical equa- 
resent reflectance intensities corresponding to these wave- 20 tion relating the absorption spectra to the predicted PO, of 
lengths or frequencies. An absorption spectrum can be the tissue. 
determined from the reflection spectrum. In that case, a The numerical model is made as robust as possible. In 
reference spectrum is taken by placing the spectral general, this is accomplished by taking a large number of 
illuminatoricollector in contact with standard reflector, such spectra at different PO, values and under different experi- 
as a 50% Spectralon Reference Standard (Labsphere Corp.) zs mental conditions. The spectra and PO, values are then 
and measuring the reflected light. The absorption spectrum processed using the PLS algorithm as described above. Most 
A(A) can be calculated by taking the log of the reference preferably, the model is sensitive only to PO,-induced 
spectrum I, (A) divided by the reflection spectrum I, (A), changes in the absorbance of the tissue, and is not affected 
following Equation 2 below: by the presence of skin. Thus, when the tissue is not exposed 
30 with a surgical procedure, reflectivity measurements are 
made at known PO, values using near infrared wavelengths A(h)=log V b  (Wl,(h)l 
Spectra for the model can be taken from tissue lying which are not strongly absorbed by the skin. In this way, 
underneath a patient’s skin or other tissue, or may be scattering processes in the skin, which are not indicative of 
collected directly from the tissue surface if it is exposed the underlying tissue’s reflectance properties, are not 
tissue. In both cases, visible and near infrared optical 3s included in the measured spectra. The model thus does not 
wavelengths are preferably used to measure the spectra. have to account for skin type, e.g., color, thickness, and 
These wavelengths are particularly advantageous in the optical quality, and other properties related to the skin which 
former case as they undergo minimal attenuation by the have a large degree of patient-to-patient variation. However, 
intervening skin layer. when wavelengths in the visible portion of the spectrum are 
Following pre-processing, a PLS algorithm is used to 40 to be used, corrections for these patient-to-patient variations 
process the x-y arrays and corresponding PO, values (step 
12) to generate a mathematical model. PLS algorithms are 
well-known for statistical analysis of x-y arrays of data 
points. Other multivariate calibration algorithms, such as 
least-squares fitting, neural networks, and principal compo- 
nents regression, can also be used to generate the model. 
These algorithms are described in Thomas, “A Primer to 
Multivariate Calibration”, Analytical Chemistry, 66: 
795-804 (1994). Processing the input data can be achieved 
using a computer and a commercially available software 
may be required. 
In addition, the model is preferably not sensitive to 
parameters associated with the optical measurement, such as 
the distance between the optical measuring device and the 
4s sample, or slight changes in the optical power. When not 
employing a tissue-contacting probe, the effect of these 
factors is minimized by taking, during step 10, a variety of 
reflection spectra and corresponding PO, measurements 
using a variety of experimental conditions. Moreover, the 
SO accuracy of the model is increased by taking measurements 
package incorporating the PLS algorithm. For instance, the at a variety of sample temperatures. Measurements taken at 
Gramsi32 software package (Galactic Industries, Inc.) can known values of PO, with patients having different degrees 
be used to perform the PLS analysis. Alternatively, a similar of fat content, skin roughness and color, height, weight, 
PLS algorithm can be coded directly into the computer. Such blood type, and other characteristics can be analyzed and 
an algorithm is defined, for example, in “Numerical Recipes ss included in the model to increase its accuracy. 
Example Book (C)”, supra. The salient features of the Preferably, a single, robust model which is invariant to 
algorithm are described below. A complete guide to the different patients is determined prior to the optical PO, 
operation of the Gramsi32 software is described in detail in measurement. Alternatively, a range of different models can 
the user’s manual corresponding to the software package. be determined and stored in the memory of a computer for 
The PLS fitting algorithm performs a statistical analysis 60 later use. In this case, the appropriate model is selected 
on the input x-y arrays and known PO, values to determine according to the patient and used with optical spectra 
a model relating absorbance spectra to the sample’s PO,. measured from the patient to determine PO,. Different 
The algorithm is based on a quantitative spectral decompo- models, for example, can correspond to patients having 
sition technique that simultaneously decomposes and different temperatures, skin color, fat content, medical 
regresses the PO, data and the spectral data. To ascertain 65 problem, etc. As a particular example, temperature can be 
their relationship, the PLS algorithm performs a statistical independently determined by a temperature sensor, e.g., a 
regressive analysis of the relationship between the absorp- thermocouple or optical pyrometer, and then analyzed to 
US 6,766,188 B2 
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select different models that are effective for different tem- 
perature ranges. 
In addition, reflection or transmission spectra and PO, 
measurements for the model can be taken from in vitro 
solutions composed of chemical species typically found in 
tissue, e.g., water, myoglobin, hemoglobin. Such solutions 
have the advantage that their properties can be easily 
changed in a controlled manner, thereby allowing a large 
number of measurements to be taken under slightly different 
conditions. The accuracy of the model can be further 
increased using statistical methods, such as cross-validation. 
In general, cross-validation is an algorithm used in combi- 
nation with PLS to obtain an objective assessment of the 
magnitude of prediction errors resulting from the model and 
to determine the optimal number of factors for the model. 
The cross-validation algorithm is included in the Gramsi32 
software package. 
The software package also singles out “outlier” x-y arrays 
which can decrease the accuracy of the model. Outlier arrays 
are erroneous data due to non-standard measurement 
conditions, such as the presence of fingerprints on the 
sample holder or a large drop in optical power. These data 
typically have dramatically different properties compared to 
data measured under more conventional measurement 
conditions, and thus decrease the accuracy of the PO, 
determination if included in the model. Similarly, outlier 
PO, measurements due to experimental deviations in the 
reference PO, measurements should not be used to calculate 
the model. 
Optical data are taken from the sample (step 18) using the 
optical PO,-measuring device described below to determine 
the PO, once the model is established and stored in a 
computer’s memory. 
The device may be the same as that used to measure data 
for the model, but calibration transfer procedures, known to 
those skilled in the art, can be used to employ the model on 
new devices. As described above, data are in the form of an 
x-y array of points, where y typically indicates the absorp- 
tion of the optical measurement, e.g., the reflectivity, as a 
function of the frequency or wavelength. Measurements 
from the sample are then multiplied with the PLS regression 
coefficients derived from the mathematical model (step 20) 
to determine the PO, (step 22). Alternatively, the data are 
multiplied by the PLS regression coefficients of the previ- 
ously determined model to determine the PO,. 
By “tissue”, as used herein, is meant any tissue or organ 
of a patient. This definition encompasses any collection of 
cells, e.g., epithelial cells, muscle cells, skin cells, or any 
specific organ, e.g., the heart, kidney, or liver, in the patient. 
The optical radiation is preferably near infrared (NIR) 
radiation, or extends from the visible into the NIR. Most 
preferably, the radiation is between about 450 nm and about 
1100 nm, where it is understood the region 450-1100 nm 
encompasses the visible and part of the near infrared spectral 
region, while 40Ck700 nm is considered visible light. This 
band includes wavelengths that undergo minimal interfer- 
ence from water absorption in the skin and other tissue, 
thereby enhancing the penetration depth of the radiation, and 
it includes a number of wavelengths that are affected by the 
phenomena of interest. 
EXAMPLE 
A near infrared spectroscopic (NIRS) fiber optic probe 
was placed over the hypothenar eminence in 6 diabetic and 
12 normal (non-diabetic) elective cardiac surgical patients to 
collect light reflected from the same muscle. Reference PO, 
and pH sensors were inserted in the abductor digiti minimi 
10 
(V) nearby. Table 1 below represents the patient character- 
istics for the 18 subjects of the study. 
TABLE 1 
5 
Patient Characteristics (N = 18) 
Age Average 65.5 r 2.1 
Gender MaleiFernale 1414 
Diabetes YesINo 6/12 
Operation CABGIValvelCABG + Valve 81515 
Data were collected every 30 seconds during surgery and 
for 6 hours following CPB while blood pressure was low- 
15 ered as a result of the surgery. Calibration equations were 
developed from one third of the data collected using partial 
least squares regression. These calibration equations were 
used along with the remaining two-thirds of the spectral data 
to investigate sensitivity of the NIRS measurement to physi- 
20 ologic changes resulting from CPB. NIRS and reference pH 
and PO, measurements were compared using the root mean 
squared deviation (RMSD). As represented by Table 2 
below, NIRS pH and PO, at baseline were compared to 
values during CPB just before rewarming commenced (low 
25 blood pressure, low temperature), after rewarming (low 
blood pressure, normal temperature) just before discontinu- 
ation of CPB, and at 6 hours following CPB (normal blood 
temperature and blood pressure) using mixed model 
ANOVA. 
For the 18 patients, NIRS pH and PO, were well corre- 
lated with the invasive measurement of pH (R2=0.84) and 
PO, (R2=0.66) with an average RMSD of 0.022+0.008 pH 
units and 623 mmHg, respectively. The agreement between 
35 NIRS non-invasive PO, and the invasive measurement is 
illustrated in FIG. 2 for one of the patients during the course 
of his surgery, where closed circles indicate the invasive 
measurement of PO, and open circles represent the 
spectroscopic, non-invasive measurement. In FIG. 2, the 
40 non-invasive (calculated) values PO, were made according 
to the present invention, and the invasive (measured) PO, 
data points were determined by a known probe. Changes in 
PO, resulting from surgical procedures such as being placed 
on the heart-lung machine (on pump) and in warming the 
patient back to normal body temperature are clearly visible 
in the course of the several-hour procedure. As illustrated in 
FIG. 2, the calibration equation or “virtual” model of tissue 
PO, accurately predicted the values measured by conven- 
tional invasive probe technology. 
As indicated in Table 2 below where the results are 
presented for all 18 patients, NIRS PO, significantly fell 
50% on initiation of CPB and remained constant throughout 
the bypass and monitored ICU period. NIR pH dropped 
ss during CPB, decreased significantly during rewarming and 
remained depressed six hours after CPB. Changes in tissue 
PO, are illustrated in FIG. 3, a graphical representation of 
the NIRS-measured tissue PO2 (mmHg) data during each of 
the four phases of the study. In conclusion, NIRS-measured 
60 muscle pH and PO, are sensitive to changes in tissue 
perfusion during cardiopulmonary bypass. Thus, the cali- 
bration or “virtual” model of tissue PO, is shown as accu- 
rately predicting the values measured by conventional inva- 
sive probe technology and optical measurement is sensitive 
65 enough to detect minor variations in blood flow resulting 
from alterations in blood pressure, temperature and meta- 
bolic demands. 
30 
4s 
so 
US 6,766,188 B2 
11 
TABLE 2 
NIRS Parameters and CPB-Induced Variables (N = 18, mean r sem) 
Baseline CPB-Cold CPB-Warm CPB + 6 
NIRS 46 r 10 22 r 5 *  27 r 5* 23 r 
Tissue PO, 
NIRS 7.36 r 0.02 7.30 r 0.02 7.20 r 0.06* 7.25 r 
Tissue pH 
Mean 83 r 2 59 r 2 62 r 2 79 r 
pressure 
Tissue 33.3 r 0.4 31.6 r 0.4 34.6 r 0.5 34.7 r 
temperature 
Blood 34.2 r 1.0 23.2 r 0.6 23.1 r 0.6 27.2 r 
hematocrit 
3* 
0.02 
2 
0.4 
0.6 
*p < 0.05 compared to baseline 
The present invention provides a method for calculating 
tissue PO, from reflectance spectra acquired from the sur- 
face of the tissue of interest. It has previously been shown 
that tissue reflectance spectra contain features related to 
venous oxygen saturation (Cingo et al., “Multivariate Cali- 
bration Modeling of Liver Oxygen Saturation Using Near 
Infrared Spectroscopy,” Proc SPIE, 3911:230-236, (2000) 
and Soller et al., “Simultaneous measurement of hepatic 
tissue pH, venous oxygen saturation and hemoglobin by 
near infrared spectroscopy,” Shock, 15: 106-111, (2001)). 
Venous oxygen saturation is typically 7&80%, falling to 
10-15% during shock. In this range, there is a linear 
correlation between oxygen saturation and oxygen partial 
pressure (PO,). The Example above used a reference mea- 
surement which measures PO, in the interstitial fluid to 
relate near infrared (and visible) spectra to tissue PO, by 
applying a multivariate calibration technique, e.g., partial 
least squares regression. By collecting a great number of 
data points as multiple parameters vary the virtual model so 
produced is accurate and robust, so that it may subsequently 
be applied to determine tissue PO, from tissue reflectance 
spectra alone. 
In general, the spectral illumination and collection steps 
may be carried out with any suitable spectrographic instru- 
ment. Thus, a single, broadband source may be scanned or 
dispersed to produce a time-sweep through the spectral band 
to illuminate the tissue of interest and collect reflected light, 
or the instrument may employ an array of different light 
sources for delivering radiation to the sample, e.g., between 
about two and about twenty light sources, each of which 
delivers radiation at a unique range of optical wavelengths. 
Each of these may be actuated in a distinctive time period, 
or modulated at a frequency, with corresponding synchro- 
nous collection or collection and demodulation, so that the 
spectral signals may be collected substantially continuously 
or simultaneously to effect speedy data collection. 
As generally illustrated in FIG. 4, a system 30 for spectral 
tissue oxygen measurement includes a spectral probe 50, 
and a processor 35, with a virtual model 40 as discussed 
above stored in or accessed by the processor 35 for trans- 
forming the optical spectrum measured from a patient into a 
PO, value for the underlying tissue. Most preferably, the 
model 40 used in the analysis step is determined once and is 
applicable to a wide variety of patients. In this case, if the 
measurements are to be made through the skin, the model is 
preferably robust enough to account for features such as skin 
color, fat content, weight, etc., which may vary from one 
patient to the next. Alternatively, a range of models 40, can 
be generated. In this case, during a procedure, the appro- 
priate model 40, is selected and used with a particular patient 
to determine the PO, of a local region of tissue. In another 
12 
exemplary embodiment, the spectral variation from features 
such as skin color, fat content, etc, are removed as suggested 
in the ’917 application previously cited. 
In a preferred embodiment, an instrument of the invention 
5 is configured with a spectral probe 50 (e.g., either with plural 
discrete light sources such as LEDs that collectively span a 
desired band, or with a broadband source and a wavelength 
scanning illumination disperser or scanning detection 
element), and with a processor that applies the virtual 
10 spectral model or calibration equation to determine the level 
of tissue PO, from a non-invasively collected tissue reflec- 
tance spectrum, and the processor also determines the pH. 
The pH may be determined by a direct sensor measurement, 
but is preferably determined by the processor using a pH 
15 calibration model (indicated by 40’ in FIG. 4) which may be 
constructed, e.g., as described in the aforesaid ’403 patent. 
The model 40’ is applied to the same or a different collected 
spectrum as used for the PO, determination. The instrument 
according to this aspect of the invention may further include 
20 diagnostic or warning determinations, which may be readily 
implemented in software. These may, for example combine 
the oxygen and pH measurements to produce a related third 
parameter, such as a measure of the tissue’s ability to utilize 
available oxygen, a measure of dysoxia, or a predictive 
25 measure of tissue recovery, demise or other critical condition 
or endpoint. Thus, the system may detect when the PO, level 
has reached a critical level at which rapid change in pH will 
occur with potentially irreversible consequences. The sys- 
tem may also indicate when blood flow has been success- 
30 fully restored, i.e. increases in tissue PO, levels to prede- 
termined levels and when adequate oxygen utilization has 
been restored, i.e. a combined increase in PO, and pH to 
satisfactory levels. For instance, calculated PO, and pH 
values can be compared to predetermined or known PO, and 
35 pH values to assess the success or failure of a resuscitation 
attempt on a patient. It may further apply different threshold 
determinations, e.g., for diabetic and non-diabetic patients, 
in issuing warning indications. 
The invention being thus described, various modifications 
40 and variations will occur to those of ordinary skill in the art, 
and all such variations are considered to be within the spirit 
and scope of the invention, as defined herein and in the 
claims appended hereto and their equivalents. 
What is claimed is: 
1. A non-invasive method for determining the localized 
irradiating the sample tissue with optical radiation such 
that the radiation propagates into the tissue to illumi- 
nate the sample tissue; 
collecting light radiation emitted from the sample tissue, 
the light radiation having been reflected or transmitted 
from the tissue; 
forming an optical reflectance spectrum of the collected 
processing the optical reflectance spectrum formed with a 
predetermined mathematical model of tissue PO, to 
determine the localized tissue PO, of the sample tissue, 
wherein the mathematical model relates optical spectra 
to known tissue PO, values in tissue. 
2. The method of claim 1, wherein the predetermined 
mathematical model of tissue PO, is constructed prior to 
processing the optical reflectance spectrum. 
3. The method of claim 2, wherein the predetermined 
collecting a plurality of optical spectra from at least one 
45 
tissue PO, of a sample tissue of a patient, comprising: 
so 
55 light radiation; and 
60 
65 mathematical model of tissue PO, is constructed by: 
representative tissue sample; 
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collecting a plurality of direct measurements of PO, from 
the same representative tissue sample over an extended 
range; and 
measurements 
with a mathematical multivariate calibration algorithm 5 the 
to determine the relationship between the optical spec- 
tra and the tissue PO, measurements. 
4. The method of claim 3, wherein the algorithm is a 
15. The method of claim 14, wherein irradiating com- 
prises irradiating the sample tissue with optical radiation not 
substantially absorbed by the covering tissue such that the 
radiation propagates through the covering tissue to irradiate 
collecting comprises collecting radiation from the sample 
tissue which passes through the covering tissue to form 
the optical reflectance spectrum. 
16. The method of claim 14, wherein the covering tissue 
processing the optical spectra and 
tissue; and 
is skin. 
has a wavelength between about 400 nm and 2500 nm, 
18. The method of claim 1, wherein the optical radiation 
is near infrared radiation, 
19. The method of claim 18, wherein the infrared radia- 
tion has a wavelength between about 450 nm and 1100 nm. 
20. The method of claim 1, wherein the localized tissue 
PO, is in a PO, range of about 0.0 to about 150 mmHg. 
21. The method of claim 1, wherein the sample tissue is 
accessed with an endoscope. 
22. A device for determining the PO, of an in vivo tissue 
sample, comprising: 
a spectrometer for irradiating the tissue sample with 
optical radiation spanning a range of visible and near 
infrared (NIR)wavelengths, and for collecting a spec- 
trum of light returned from the tissue sample, the 
spectrometer forming a spectral representation thereof; 
and 
a microprocessor operative on the spectral representation 
to calculate the tissue PO, of the sample, the micro- 
processor being programmed to compare the spectral 
representation to a predetermined mathematical model 
of tissue PO, to determine the PO, of the sample. 
23. The device of claim 22, wherein the spectrometer 
emits visible wavelengths above 400 nm. 
24. The device of claim 22, wherein the predetermined 
mathematical model of tissue PO, relates a spectral repre- 
sentation of a representative tissue to tissue PO,. 
partial least-squares fitting algorithm. 
between the optical spectra and the tissue PO, measure- 
ments is linear. 
6. The method of claim 3, wherein the relationship 
between optical spectra and the tissue PO, measurements is 
non-linear. 
7. The method of claim 3, further comprising collecting a 
tissue value over an extended range of at least one parameter 
selected from the group consisting of temperature and pH, 
prior to processing the optical spectra and PO, measure- 
ments. 
8. The method of claim 3, wherein the plurality of optical 
spectra are collected from the at least one representative 
tissue sample in vitro. 
9. The method of claim 1, further comprising determining 
tissue pH simultaneously from the optical reflectance spec- 25 
trum. 
10. The method of claim 9, further comprising detecting 
a dysoxic tissue state. 
11. The method of claim 9, further comprising determin- 
ing a level of ischemia of the sample tissue using both the 30 
calculated pH and localized tissue PO, data. 
12. The method of claim 9, further comprising determin- 
ing the success or failure of a resuscitation by comparing the 
calculated pH and localized tissue PO, data to predeter- 
mined values for pH and tissue PO,. 
13. The method of claim 1, wherein the sample tissue 
comprises muscle or organ. 
14. The method of claim 1, wherein the sample tissue is 
5.  The method Of 3, wherein the 17, The method of claim 1, wherein the optical radiation 
20 
35 
disposed underneath a covering tissue of the patient. * * * * *  
